These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27099451)

  • 1. Atypical onset of bicalutamide-induced liver injury.
    Yun GY; Kim SH; Kim SW; Joo JS; Kim JS; Lee ES; Lee BS; Kang SH; Moon HS; Sung JK; Lee HY; Kim KH
    World J Gastroenterol; 2016 Apr; 22(15):4062-5. PubMed ID: 27099451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-related hepatotoxicity and hepatic failure following combined androgen blockade.
    Castro Beza I; Sánchez Ruiz J; Peracaula Espino FJ; Villanego Beltrán MI
    Clin Transl Oncol; 2008 Sep; 10(9):591-2. PubMed ID: 18796378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bicalutamide-associated fulminant hepatotoxicity.
    O'Bryant CL; Flaig TW; Utz KJ
    Pharmacotherapy; 2008 Aug; 28(8):1071-5. PubMed ID: 18657023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
    J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer tissue is masked by bicalutamide: a case report.
    Ellinger J; Bastian PJ; Biermann K; Schmidt ME; Textor J; Bollmann D; Zhou H; Müller SC
    Eur J Med Res; 2007 May; 12(5):212-5. PubMed ID: 17513193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depression related to (neo)adjuvant hormonal therapy for prostate cancer.
    van Tol-Geerdink JJ; Leer JW; van Lin EN; Schimmel EC; Stalmeier PF
    Radiother Oncol; 2011 Feb; 98(2):203-6. PubMed ID: 21256610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of gynecomastia induced by bicalutamide].
    Haddad E
    Ann Urol (Paris); 2006 Dec; 40 Suppl 2():S49-52. PubMed ID: 17361921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy Plus GnRH Analogue
    Buwenge M; Deodato F; Macchia G; Siepe G; Zhao X; Valicenti RK; Cilla S; Alitto AR; Ntreta M; Bisello S; Mantini G; Valentini V; Morganti AG; Cammelli S
    Anticancer Res; 2019 Nov; 39(11):6373-6378. PubMed ID: 31704870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bicalutamide-associated hallucinations in a metastatic prostate cancer patient: A case report.
    Turkkan G; Dogan C; Tek B
    J Oncol Pharm Pract; 2020 Jun; 26(4):1029-1031. PubMed ID: 31707924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
    Mason M; Maldonado Pijoan X; Steidle C; Guerif S; Wiegel T; van der Meulen E; Bergqvist PB; Khoo V
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):190-6. PubMed ID: 23257248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [DRUG-INDUCED INTERSTITIAL LUNG DISEASE DURING COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE AND LEUPRORELIN ACETATE FOR PROSTATE CANCER].
    Maeda K; Osafune T; Masuda Y; Takeda T; Kageyama S; Narita M; Kawauchi A
    Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):36-40. PubMed ID: 31956217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.
    Beebe-Dimmer JL; Ruterbusch JJ; Bylsma LC; Gillezeau C; Fryzek J; Schultz NM; Flanders SC; Barlev A; Heath E; Quek RGW
    Adv Ther; 2018 Sep; 35(9):1438-1451. PubMed ID: 29946798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients].
    Salvador C; Planas J; Raventós C; Ropero J; Placer J; López MA; Morote J
    Actas Urol Esp; 2012 Apr; 36(4):205-9. PubMed ID: 22178349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New indication sought for bicalutamide.
    Oncology (Williston Park); 2000 May; 14(5):654, 772. PubMed ID: 10853458
    [No Abstract]   [Full Text] [Related]  

  • 16. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
    Klotz L; Drachenberg D; Singal R; Aprikian A; Fradet Y; Kebabdjian M; Zarenda M; Chin J
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tamoxifen in reducing bicalutamide-induced gynaecomastia and breast pain.
    Nuttall MC; Harris JP; Dawkins GP
    BJU Int; 2007 Feb; 99(2):243-4. PubMed ID: 17313420
    [No Abstract]   [Full Text] [Related]  

  • 18. Images in clinical medicine. Gynecomastia induced by prostate-cancer treatment.
    Michalopoulos NV; Keshtgar MR
    N Engl J Med; 2012 Oct; 367(15):1449. PubMed ID: 23050528
    [No Abstract]   [Full Text] [Related]  

  • 19. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of bicalutamide-induced breast events.
    Sieber PR
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1773-9. PubMed ID: 18062751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.